https://www.fool.com/investing/general/2013/04/02/what-are-the-opportunities-ahead-for-abbott-labs-i.aspx
https://www.fool.com/investing/general/2013/03/15/does-novo-nordisk-dividend-have-room-to-soar.aspx
https://www.fool.com/investing/general/2013/01/25/should-you-replace-this-replacement-specialist.aspx
https://www.fool.com/investing/general/2013/02/06/1-reason-dendreon-continues-to-march-higher.aspx
https://www.fool.com/investing/general/2013/02/07/will-the-fda-give-this-drug-the-green-light.aspx
https://www.fool.com/investing/general/2013/02/11/1-must-watch-intuitive-surgical-metric.aspx
https://www.fool.com/investing/general/2013/02/20/questcors-biggest-opportunity.aspx
https://www.fool.com/investing/general/2013/03/25/why-apple-like-tiger-woods-will-return-to-greatnes.aspx
https://www.fool.com/investing/general/2013/03/19/does-st-jude-medical-have-a-rock-solid-dividend.aspx
https://www.fool.com/investing/general/2013/02/19/what-you-need-to-know-about-express-scripts-earnin.aspx
https://www.fool.com/investing/general/2013/03/19/does-mercks-dividend-have-room-to-soar.aspx
https://www.fool.com/investing/general/2013/02/22/why-health-insurers-had-a-horrible-week.aspx
https://www.fool.com/investing/general/2013/03/19/does-unitedhealth-group-have-a-rock-solid-dividend.aspx
https://www.fool.com/investing/general/2013/02/04/hyperion-surges-on-fda-approval-but-whats-next.aspx
https://www.fool.com/investing/general/2013/04/09/should-you-buy-abbott-labs-today.aspx
https://www.fool.com/investing/general/2013/03/01/intuitive-surgical-crashes-in-late-trading.aspx
https://www.fool.com/investing/general/2013/01/25/abbott-labs-not-abbvie-is-acting-like-a-spin-off.aspx
https://www.fool.com/investing/general/2013/03/12/will-this-obamacare-rule-hurt-baby-formula-sales.aspx
https://www.fool.com/investing/general/2013/02/22/left-at-the-altar-no-buyout-for-this-health-care-g.aspx
https://www.fool.com/investing/general/2013/03/12/merck-gains-on-cholesterol-drug-hopes.aspx
https://www.fool.com/investing/general/2013/02/11/a-must-watch-mako-surgical-metric.aspx
https://www.fool.com/investing/general/2013/04/04/why-sell-abbott-labs-3-reasons-to-consider.aspx
https://www.fool.com/investing/general/2013/02/19/today-medicare-advantage-turns-into-a-disadvantage.aspx
https://www.fool.com/investing/general/2013/02/21/1-way-abbott-labs-can-fix-health-care.aspx
https://www.fool.com/investing/general/2013/02/19/unitedhealths-annual-check-up.aspx
https://www.fool.com/investing/general/2013/02/07/can-these-two-drugs-get-fda-approval.aspx
https://www.fool.com/investing/general/2013/03/11/how-big-pharma-avoids-billions-in-taxes.aspx
https://www.fool.com/investing/general/2013/02/13/can-peregrine-match-celgene-no.aspx
https://www.fool.com/investing/general/2013/03/15/does-bristol-myers-dividend-have-room-to-soar.aspx
https://www.fool.com/investing/general/2013/02/19/healthcares-battle-for-the-mailbox.aspx
https://www.fool.com/investing/general/2013/02/10/how-long-can-this-pharma-gold-rush-last.aspx
https://www.fool.com/investing/general/2013/03/14/does-novartis-dividend-have-room-to-soar.aspx
https://www.fool.com/investing/general/2013/02/21/can-jj-and-pharmacyclics-help-fix-health-care.aspx
https://www.fool.com/investing/general/2013/02/04/a-dark-cloud-is-lifted-from-cyberonics.aspx
https://www.fool.com/investing/general/2013/03/05/robotic-surgery-errors-is-intuitive-surgical-reall.aspx
https://www.fool.com/investing/general/2013/01/30/what-questcor-investors-absolutely-must-watch.aspx
https://www.fool.com/investing/general/2013/01/25/a-key-earnings-report-in-cardiac-medical-devices.aspx
https://www.fool.com/investing/general/2013/03/23/why-the-health-care-arms-race-hurts-this-stock.aspx
https://www.fool.com/investing/general/2013/02/21/1-way-we-can-fix-health-care.aspx
https://www.fool.com/investing/general/2013/02/08/an-obesity-treatment-doomed-for-failure.aspx
https://www.fool.com/investing/general/2013/03/11/will-obamacares-medicaid-expansion-pay-off.aspx
https://www.fool.com/investing/general/2013/03/27/3-reasons-to-buy-abbvie-today.aspx
https://www.fool.com/investing/general/2013/02/25/dendreons-path-to-profitability.aspx
https://www.fool.com/investing/general/2013/03/23/obamacare-vs-arkansas-the-great-health-insurance-d.aspx
https://www.fool.com/investing/general/2013/02/27/news-or-noise-abbott-labs-mead-johnson-chinese-mil.aspx
https://www.fool.com/investing/general/2013/02/12/did-abbvie-and-zoetis-add-value-for-abbott-and-pfi.aspx
https://www.fool.com/investing/general/2013/03/15/does-amgens-dividend-have-room-to-soar.aspx
https://www.fool.com/investing/general/2013/02/12/arena-investors-you-need-more-than-a-blockbuster.aspx
https://www.fool.com/investing/general/2013/02/04/what-to-make-of-questcor-management.aspx
https://www.fool.com/investing/general/2013/03/14/does-johnson-johnsons-dividend-have-room-to-soar.aspx
https://www.fool.com/investing/general/2013/03/08/want-insurance-head-to-wal-mart.aspx
https://www.fool.com/investing/general/2013/03/01/intuitives-fda-inquiry-nightmare-or-noise.aspx
https://www.fool.com/investing/general/2013/02/20/a-health-insurance-opportunity-risk-or-both.aspx
https://www.fool.com/investing/general/2013/03/28/what-are-the-risks-with-abbvie.aspx
https://www.fool.com/investing/general/2013/03/01/what-to-make-of-biosimilar-delays.aspx
https://www.fool.com/investing/general/2013/03/14/does-pdl-biopharmas-dividend-have-room-to-soar.aspx
https://www.fool.com/investing/general/2013/04/03/what-should-investors-watch-with-abbvie.aspx
https://www.fool.com/investing/general/2013/03/07/will-these-obamacare-supporters-get-burned.aspx
https://www.fool.com/investing/general/2013/02/08/an-unsurprising-pipeline-failure.aspx
https://www.fool.com/investing/general/2013/03/19/does-medtronic-have-a-rock-solid-dividend.aspx
https://www.fool.com/investing/general/2013/03/05/can-anything-stop-johnson-johnson-2.aspx
https://www.fool.com/investing/general/2013/02/25/down-85-why-affymax-is-getting-crushed-this-mornin.aspx
https://www.fool.com/investing/general/2013/02/06/up-25-the-anti-dentites-nightmare-stock-surges.aspx
https://www.fool.com/investing/general/2013/02/04/should-you-buy-merck-after-this-selloff.aspx
https://www.fool.com/investing/general/2013/03/28/what-are-the-risks-for-abbott-labs-investors.aspx
https://www.fool.com/investing/general/2013/03/12/is-the-fda-to-blame-for-your-bad-hip.aspx
https://www.fool.com/investing/general/2013/03/15/does-pfizers-dividend-have-room-to-soar.aspx
https://www.fool.com/investing/general/2013/03/07/are-drug-prices-too-low.aspx
https://www.fool.com/investing/general/2013/03/14/does-tevas-dividend-have-room-to-soar.aspx
https://www.fool.com/investing/general/2013/02/11/1-powerhouse-drug-in-celgenes-pipeline.aspx
https://www.fool.com/investing/general/2013/03/07/this-report-explains-a-key-trend-in-pharmaceutical.aspx
https://www.fool.com/investing/general/2013/01/25/breaking-down-health-cares-biggest-earnings-report.aspx
https://www.fool.com/investing/general/2013/03/24/intuitive-surgicals-march-madness.aspx
https://www.fool.com/investing/general/2013/02/26/hot-off-the-press-mako-surgical-earnings.aspx
https://www.fool.com/investing/general/2013/02/13/can-a-new-ceo-turn-this-insurer-around.aspx
https://www.fool.com/investing/general/2013/03/05/ignoring-the-health-insurance-mandate.aspx
https://www.fool.com/investing/general/2013/02/21/repros-soars-and-abbvie-might-suffer.aspx
https://www.fool.com/investing/general/2013/02/06/the-hole-in-abbvies.aspx
https://www.fool.com/investing/general/2013/03/14/does-astrazenecas-dividend-have-room-to-soar.aspx
https://www.fool.com/investing/general/2013/02/11/novo-nordisk-fails-sanofi-and-lilly-win.aspx
https://www.fool.com/investing/general/2013/03/15/this-is-an-intuitive-surgical-buying-opportunity.aspx
https://www.fool.com/investing/general/2013/02/22/this-company-forgot-the-meaning-of-revenue.aspx
https://www.fool.com/investing/general/2013/03/22/the-future-of-astrazeneca-pharmas-biggest-dividend.aspx
https://www.fool.com/investing/general/2013/02/27/news-or-noise-accretive-healths-dive.aspx
https://www.fool.com/investing/general/2013/03/21/dont-believe-this-obamacare-cost-projection.aspx
https://www.fool.com/investing/general/2013/02/21/is-intuitive-hedging-its-bets.aspx
https://www.fool.com/investing/general/2013/02/25/is-there-any-hope-left-for-affymax.aspx
https://www.fool.com/investing/general/2013/02/22/biotech-investors-please-dont-make-this-mistake.aspx
https://www.fool.com/investing/general/2013/02/07/the-real-opportunity-for-health-care.aspx
https://www.fool.com/investing/general/2013/03/19/does-quality-systems-have-a-rock-solid-dividend.aspx
https://www.fool.com/2013/05/02/pull-quote-3.aspx
https://www.fool.com/investing/general/2013/03/24/forget-obamacare-apples-iphone-could-help-save-hea.aspx
https://www.fool.com/investing/general/2013/03/07/bad-news-for-blood-thinners.aspx
https://www.fool.com/investing/general/2013/03/14/does-questcors-dividend-have-room-to-soar.aspx
https://www.fool.com/investing/general/2013/02/19/peregrine-investors-once-bitten-twice-shy.aspx
https://www.fool.com/investing/general/2013/03/01/is-this-johnson-johnson-court-case-news-or-noise.aspx
https://www.fool.com/investing/general/2013/02/04/humana-surges-higher-after-earnings.aspx
https://www.fool.com/investing/general/2013/02/12/celgenes-ceo-talks-new-approvals-future-opportunit.aspx
https://www.fool.com/investing/general/2013/03/15/does-eli-lillys-dividend-have-room-to-soar.aspx
https://www.fool.com/investing/general/2013/02/19/intuitive-has-its-eye-on-this-newcomer.aspx
